Satellite Sessions

October 4 | 12:30-14:30

Abbot Laboratories | October 4 | 12:30-14:30

TBA

Pfizer Pharmaceuticals Israel | October 4 | 12:30-14:30

TBA

Boehringer Ingelheim Israel LTD | October 4 | 12:30-14:30

SGLT2 inhibition in heart failure: optimizing patient benefit in clinical practice

 

Click here to view session agenda

Novartis Israel | October 4 | 12:30-14:30

Bending the curve of life- New era in Hypercholesterolemia management


Click here to view session agenda

October 5 | 12:30-14:30

Bayer Israel | October 5 | 12:30-14:30

TBA

Novo Nordisk | October 5 | 12:30-14:30

New insights on CV risk reduction in T2D- the role of GLP-1 RA

AstraZeneca (Israel) | October 5 | 12:30-14:30

SGLT2 Inhibition in Heart Failure: Recalculating the HFrEF Treatment Paradigm

Medison | October 5 | 12:30-14:30

TBA

Medtronic | October 5 | 12:30-14:30

TBA